{"id":"NCT02642432","sponsor":"AbbVie","briefTitle":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis","officialTitle":"A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-07","primaryCompletion":"2016-10-27","completion":"2017-02-10","firstPosted":"2015-12-30","resultsPosted":"2017-09-26","lastUpdate":"2021-07-13"},"enrollment":146,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus Infection","Chronic Hepatitis C","Compensated Cirrhosis"],"interventions":[{"type":"DRUG","name":"ABT-493/ABT-530","otherNames":["ABT-493 also known as glecaprevir","ABT-530 also known as pibrentasvir","MAVYRET"]}],"arms":[{"label":"ABT-493/ABT-530","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the safety and efficacy of ABT-493/ABT-530 following 12 weeks of treatment in adults with chronic Hepatitis C Virus Infection genotype 1, 2, 4, 5 or 6 infection and compensated cirrhosis.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","timeFrame":"12 weeks after the last actual dose of study drug","effectByArm":[{"arm":"ABT-493/ABT-530","deltaMin":99.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28818546","31568620","30977945","30923816","30529905","30012435"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":146},"commonTop":["FATIGUE","HEADACHE","PRURITUS","NAUSEA","DIARRHOEA"]}}